Atopic Dermatitis Clinical Trials Market Size

Atopic Dermatitis Clinical Trials Market Size

Atopic Dermatitis Clinical Trials Market size was valued at USD 2.4 billion in 2023 and will exhibit growth at 11.4% to reach USD 6.4 billion by 2032. Rising prevalence of atopic dermatitis is a major factor accelerating the growth of this market.

To get key market trends

  Download Free Sample

For instance, as per the Global Report on atopic dermatitis 2022, the prevalence of atopic dermatitis is high, affecting up to 20% of children and up to 10% of adults. The global burden of atopic dermatitis ranks 15th among non-fatal diseases and holds the top position for skin-related conditions when measured by disability-adjusted life years. Thus, with such increasing prevalence of atopic dermatitis, investments in research and development activities are growing, thereby accelerating the atopic dermatitis clinical trials market growth.
 

Atopic dermatitis, often referred to as eczema, is a chronic skin condition characterized by inflammation and itching. It commonly appears as dry, red, and itchy patches on the skin, which can sometimes ooze or crust over. Clinical trials for atopic dermatitis (AD) are essential for developing and evaluating new treatments and therapies aimed at managing the symptoms of this chronic skin condition. These trials typically follow a structured process and involve various phases to assess safety, efficacy, and tolerability.